Achillion

Apellis Pharmaceuticals

The company develops and commercialises therapeutic compounds targeting the complement system for patients with haematological, ophthalmological and rare kidney diseases.

APLS

This biopharmaceutical company develops complement-based therapies to treat autoimmune and inflammatory diseases for patients with conditions like paroxysmal nocturnal haemoglobinuria and geographic atrophy.

Actelion Holding Ltd

This biopharmaceutical company develops and commercialises orphan drugs to treat rare diseases, including pulmonary arterial hypertension, for patients worldwide.

Actelion

This company develops and manufactures pharmaceutical drugs to treat orphan diseases such as pulmonary arterial hypertension for patients and healthcare providers globally.

Annexon Biosciences

This biopharmaceutical company develops complement-based therapies for patients with autoimmune, neurodegenerative and ophthalmic diseases of the body, brain and eye.

True North Therapeutics

This biotechnology company develops monoclonal antibodies targeting the complement system to treat patients with rare blood, kidney and skin diseases.

Curzion Pharmaceuticals

This biopharmaceutical company develops oral small molecule therapies to treat patients with rare fibrotic conditions like diffuse cutaneous systemic sclerosis.

Principia Biopharma

The company develops oral small molecule therapies for patients with immune-mediated diseases and cancer.